tbuckley/cabot-search huggingface dataset:
Corrigendum to “Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease” [J Hepatol 2015;63:763–765]
Authors: Kalyan Ram Bhamidimarri, Frank Czul, Adam Peyton, Cynthia Levy, Maria Hernandez, Lennox Jeffers, David Roth, Eugene Schiff, Christopher O’Brien, Paul Martin
Journal: Journal of Hepatology (2015)
IMS-KN08 plays a critical role in human lung carcinogenesis by interacting with and activating RHOA
Authors: Chie Suzuki, Yataro Daigo, Nobuhisa Ishikawa, Tatsuya Kato, Satoshi Hayama, Yusuke Nakamura
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

2336 

To investigate the mechanisms of lung carcinogenesis and identify genes that might be useful as diagnostic markers or targets for development of new molecular therapies, we searched for genes that were specifically up-regulated in non-small cell lung cancers (NSCLC) by means of cDNA microarray with systematic protein-expression analysis of hundreds of clinical samples on tissue microarray and high-throughput screening of loss-of-function phenotypes with RNAi systems. Gene-expression profiles of NSCLCs and subsequent functional analyses revealed that human IMS-KN08 was transactivated in lung-cancer cells and appeared to play a significant role in pulmonary carcinogenesis. Immunohistochemical staining using tumor tissue microarrays confirmed that IMS-KN08 protein was frequently increased in NSCLCs. Induction of small interfering RNAs (siRNAs) against IMS-KN08 in NSCLC cells suppressed its expression and resulted in growth suppression; moreover, siRNA treatment yielded cells with larger morphology and multiple nuclei, which subsequently died. On the other hand, induction of exogenous expression of IMS-KN08 enhanced the migrating ability of mammalian cells by interacting directly with RHOA, a small GTPase, and inducing actin stress fibers. Our data imply that up-regulation of IMS-KN08 is a common feature of the carcinogenetic process in lung tissue and the IMS-KN08-RHOA complex is likely to be essential for the growth-promoting pathway and aggressive features of lung cancers Selective suppression of the pathway might hold promise for development of novel therapeutic drugs for treatment of lung-cancer patients.
Long-Term Ozone Exposure Increases the Risk of Developing the Acute Respiratory Distress Syndrome
Authors: Lorraine B. Ware, Zhiguo Zhao, Tatsuki Koyama, Addison K. May, Michael A. Matthay, Fred W. Lurmann, John R. Balmes, Carolyn S. Calfee
Journal: American Journal of Respiratory and Critical Care Medicine (2015)

The contribution of air pollution to the risk of acute respiratory distress syndrome (ARDS) is unknown.
Prognostic value of tumor-infiltrating lymphocytes in Epstein–Barr virus-associated gastric cancer
Authors: B.W. Kang, A.N. Seo, S. Yoon, H.I. Bae, S.W. Jeon, O.K. Kwon, H.Y. Chung, W. Yu, H. Kang, J.G. Kim
Journal: Annals of Oncology (2015)
Abstract 13861: Trends in Utilization of Mechanical Circulatory Assist Devices in Patients Presenting with ST Elevation Myocardial Infarction
Authors: Shikhar Agarwal, Venu Menon
Journal: Circulation (2014)

Despite significant controversy about the efficacy, mechanical circulatory support (MCS) is often utilized in patients with cardiogenic shock after ST elevation myocardial infarction (STEMI). We aimed to characterize the trends and outcomes following the use of MCS devices in patients presenting with STEMI. Methods: We used the 2003-2011 US Nationwide Inpatient Sample for this study. All admissions with a principal diagnosis of STEMI were identified using standard ICD codes. MCS devices included intra aortic balloon pump or Impella and were identified using ICD procedure codes. Results: Of a total of 372984 admissions with STEMI, we identified 35685 (9.3%) cases that required MCS. Over the study duration, there was a significant increase in the utilization of MCS from 7.6% in 2003 to 10.5% in 2011 (Panel A). This increase in the use of MCS was accompanied by a significant increase in the incidence of cardiogenic shock in the study population (Panel A). Despite an increase in the overall cardiogenic shock incidence, there was a significant increase in the relative utilization of MCS in cardiogenic shock (Panel B) during the study duration. Of all the cardiogenic shock cases, utilization of MCS increased from 48.6% in 2003 to 57.4% in 2009, followed by a small decline to 54.7% in 2011. Among patients with cardiogenic shock, in-hospital mortality rate was 31.5% in patients with MCS as compared to 42.4% in those treated without MCS (p&lt;0.001). Using multivariable hierarchical regression modeling, we found a significant reduction in adjusted in-hospital mortality with MCS, among patients with cardiogenic shock [OR (95% CI): 0.82 (0.77-0.88), p&lt;0.001]. Conclusions: Over the last decade, there has been a significant increase in the utilization of MCS in patients with STEMI. In contrast to the results of the IABP trial, the use of MCS was associated with a significant reduction in in-hospital mortality in this real world nationwide experience.
<i>Notes from the Field</i>: Injection Safety and Vaccine Administration Errors at an Employee Influenza Vaccination Clinic — New Jersey, 2015
Authors: Laura Taylor, Rebecca Greeley, Jill Dinitz-Sklar, Nicole Mazur, Jill Swanson, JoEllen Wolicki, Joseph Perz, Christina Tan, Barbara Montana
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

On September 30, 2015, the New Jersey Department of Health (NJDOH) was notified by an out-of-state health services company that an experienced nurse had reused syringes for multiple persons earlier that day. This occurred at an employee influenza vaccination clinic on the premises of a New Jersey business that had contracted with the health services company to provide influenza vaccinations to its employees. The employees were to receive vaccine from manufacturer-prefilled, single-dose syringes. However, the nurse contracted by the health services company brought three multiple-dose vials of vaccine that were intended for another event. The nurse reported using two syringes she found among her supplies to administer vaccine to 67 employees of the New Jersey business. She reported wiping the syringes with alcohol and using a new needle for each of the 67 persons. One of the vaccine recipients witnessed and questioned the syringe reuse, and brought it to the attention of managers at the business who, in turn, reported the practice to the health services company contracted to provide the influenza vaccinations.
The <i>Tara</i> Oceans Project: New Opportunities and Greater Challenges Ahead
Authors: Houjin Zhang, Kang Ning
Journal: Genomics Proteomics & Bioinformatics (2015)

In the May 22, 2015 issue of Science magazine, several articles (including the editorial, research papers, and perspectives) were published on the Tara Oceans Project and studies related to ocean microbes [1], [2], [3], [4], [5], [6], [7], [8]. This represents truly a milestone for studies in both ocean ecology and microbial communities. As stated on the European Molecular Biology Laboratory (EMBL) website (http://www.embl.de/tara-oceans/start/): “Tara Oceans results reveal climate change insights, and a treasure trove of novel species and genes.”

The Tara Oceans project is led by the EMBL and was initiated in September 2009. Over the past few years, this project has collected more than 30,000 samples containing millions of small organisms from more than 200 ocean stations. Most samples were collected by Tara, a 110-foot research schooner that has sampled microscopic plankton at depths of up to 2000 m in all the major oceanic regions, such as the North Atlantic Ocean, during expeditions from 2009 through 2013 [8]. This project has garnered interest from numerous research groups worldwide, and received press coverage on several occasions since 2009 [9].

Three major studies related to microbial big-data mining have been performed on the samples and data collected in the Tara Oceans project. The first is a study examining the ocean microbial function and community structure [8]. The group led by Peer Bork analyzed 7.2 TB of metagenomic data (a very small fraction of the whole project) from 243 Tara Oceans samples collected from 68 locations. They discovered millions of novel sequences from viruses, prokaryotes, and picoeukaryotes, and indicated that the temperature, rather than other environmental factors, plays the most important role in shaping the microbial community compositions. The second study is of the ocean virome [3]. Brum et al. defined the upper-ocean viral community pan and core gene sets based on 43 Tara Oceans expedition samples. Their analyses support the seed-bank hypothesis, which defines “the viral community as a reservoir of dormant individuals that can potentially be resuscitated in the future under different environmental conditions” [10]. This hypothesis may help explain how oceanic viral communities maintain high local diversity. The third study is of ocean plankton interactome interpretation. Lima-Mendez et al. found that the ocean plankton interaction network is driven by both local and global patterns. Moreover, this study provided a rich resource for ocean food webs as well as biological components in ocean models [4]. Other studies published include analyses of the diversity of eukaryotic plankton [1], overview of the global ocean microbiome based on the Tara Oceans project [2], and the ways environmental characteristics of Agulhas rings affecting inter-ocean plankton transport [5].
Vinorelbine as first-line chemotherapy for metastatic breast carcinoma.
Authors: A Romero, M G Rabinovich, C T Vallejo, J E Perez, R Rodriguez, M A Cuevas, M Machiavelli, J A Lacava, M Langhi, L Romero Acuña
Journal: Journal of Clinical Oncology (1994)

PURPOSE A phase II trial was performed to evaluate the efficacy and toxicity of vinorelbine (VNB) as first-line chemotherapy for metastatic breast carcinoma. PATIENTS AND METHODS Between August 1991 and February 1993, 45 patients with metastatic breast cancer were entered onto the study. Therapy consisted of VNB 30 mg/m2 diluted in 500 mL of normal saline administered as a 1-hour intravenous infusion. Injections were repeated weekly until evidence of progressive disease (PD) or severe toxicity developed. RESULTS One patient was considered not assessable for response. An objective response (OR) was observed in 18 of 44 patients (41%; 95% confidence interval, 26% to 56%). Three patients (7%) had a complete response (CR) and 15 (34%) had a partial response (PR). The median time to treatment failure for the entire group was 6 months (range, 1 to 15), and the median duration of response was 9 months (range, 1 to 15). The median survival duration has not been reached yet. There were no treatment-related deaths. The dose-limiting toxicity was myelosuppression. Leukopenia occurred in 35 patients (78%) and was grade 3 or 4 in 16 (36%). Phlebitis was observed in 19 of 29 patients (66%) who did not have central implantable venous systems. Fifteen patients (33%) developed peripheral neurotoxicity. Myalgia occurred in 20 patients (44%). CONCLUSION VNB is an active drug against metastatic breast cancer with moderate toxicity, which justifies further evaluation in association with other agents.
Comparison of <i>de novo</i> vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations of 11q23
Authors: W. Blum, K. Mrózek, K. Maharry, S. C. Raimondi, A. J. Carroll, R. A. Larson, J. D. Rowley, C. D. Bloomfield
Journal: Journal of Clinical Oncology (2005)

6549 Background: Recurring balanced chromosome aberrations involving band 11q23 have been detected in both de novo AL/MDS and therapy-related AL/MDS (t-AL/MDS), but de novo 11q23 AL/MDS has seldom been compared directly with 11q23 t-AL/MDS. Methods: We compared pretreatment characteristics and overall survival (OS) of 128 adult patients (pts) with de novo 11q23 AL (n=126) or MDS (n=2) enrolled onto CALGB study 8461 with those of 131 adults with 11q23 t-AL (n=118) or t-MDS (n=13) studied at the IWBCAt-AL/MDS. Results: In analyses restricted to acute myeloid leukemia (AML) and MDS, pts with de novo disease had higher platelet counts (P=.008), and % marrow (P<177>.0001) and blood blasts (P=.0008) than pts with t-AML/MDS, whereas other pretreatment characteristics were similar. The 1- and 3-year OS rates were 43% and 20% for de novo AML/MDS pts, but only 25% and 8%, respectively, for t-AML/MDS pts (P<.001, see Table). In pts receiving stem cell transplantation (SCT), de novo AML/MDS pts (n=30) had 1- and 3-year OS rates of 80% and 37% compared with, respectively, 43% and 20% for t-AML/MDS pts (n=20, P<.01). The difference in OS between de novo AML/MDS and t-AML/MDS was mainly due to the significantly better OS of pts with de novo AML/MDS harboring t(9;11)(p22;q23) or t(11;19)(q23;p13.3). There were no significant differences in pretreatment characteristics or OS between pts with de novo (n=31) and therapy-related (n=11) acute lymphoblastic leukemia (ALL) with 11q23 abnormalities, the majority of whom had t(4;11)(q21;q23). Conclusions: OS of pts with de novo AML/MDS was superior to OS of t-AML/MDS pts, primarily because of more favorable outcomes of de novo AML/MDS with t(9;11)(p22;q23) and t(11;19)(q23;p13.3). Although SCT improved OS of both de novo and therapy-related pts, the outcome for both types of 11q23 AML/MDS remains poor, highlighting the need for novel therapeutic approaches. Author Disclosure OS of de novo and t-AL/MDS with balanced 11q23 abnormalities [*11q23 breakpoint partner] Type of AL/MDS All 11q23 AML/MDS cases 9p22* 6q27* 19p13.1* 19p13.3* Other 11q23 AML/MDS pts with SCT ALL 4q21* De novo #pts 1-yr 3-yr 97 43% 20% 42 48% 31% 17 47% 12% 11 27% 18% 7 57% 14% 20 35% 15% 30 80% 37% 27 41% 22% Therapy-related #pts 1-yr 3-yr 120 25% 8% 65 19% 6% 8 38% 13% 15 53% 18% 14 26% 26% 18 29% 0% 20 43% 20% 11 46% 46% P value <.001 <.001 .78 .69 .04 .13 <.01 .32 No significant financial relationships to disclose.
BMA is in denial
Authors: Peter L Hall
Journal: BMJ (2007)

Despite the evidence that the 2004 charging regulations that bar access to free NHS hospital care violate refused asylum seekers' human rights,1 the BMA has never acknowledged the fact. Now the government has raised the stakes immeasurably2—the years of confusion, procrastination, hounding, and denial of hospital care3 will appear small beer if its threat to also ban access to free primary care is implemented this October, …
En route to disentangle the impact and neurobiological substrates of early vocalizations: Learning from Rett syndrome
Authors: Peter B Marschik, Walter E Kaufmann, Sven Bölte, Jeff Sigafoos, Christa Einspieler
Journal: Behavioral and Brain Sciences (2014)

Abstract Research on acoustic communication and its underlying neurobiological substrates has led to new insights about the functioning of central pattern generators (CPGs). CPG-related atypicalities may point to brainstem irregularities rather than cortical malfunctions for early vocalizations/babbling. The “vocal pattern generator,” together with other CPGs, seems to have great potential in disentangling neurodevelopmental disorders and potentially predict neurological development.
Effects of hyperglycemia and dexamethasone on expression of thioredoxin-interacting protein (TXNIP) expression and reactive oxygen species (ROS) in multiple myeloma-derived cell lines
Authors: R. Friday, Charles Wendling, Johnathan Ledet, Francesco Turturro
Journal: Cancer Research (2008)

4341   BACKGOURND: We have recently identified TXNIP as one of the gene products particularly sensitive to the level of glucose in metastatic breast cancer-derived cells ( Clin Cancer Res 2007;15:3724 ). The level of reactive oxygen species (ROS) was upregulated by the glucose-induced expression of TXNIP making metastatic breast cancer cells more vulnerable to oxidative stress as compared to non-metastatic malignant/normal breast derived cell lines. In the current study, we examined the TXNIP level, thioredoxin (TRX)-activity and ROS production in response to glucose and dexamethasone (DEX) as one of the most active single agent in multiple myeloma cell lines at various level of aggressiveness (NCIH929, U266B1, ARH77 MC/CAR).  EXPERIMENTAL DESIGN: Cells were grown either in 5 or 20 mM glucose chronically. For experiments involving DEX, cells were cultured in RPMI/ 10% FBS 20 mM glucose and 25 uM DEX for 24 h. Semiquantitative reverse transcription-PCR (RT-PCR) was used to assess TXNIP RNA expression in response to glucose. ROS were detected by 5-6-chloromethyl-29,79-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) and measured for mean fluorescence intensity with flow cytometry. TRX-activity was assayed by the insulin disulfide-reducing assay. Proliferation was evaluated using Cell Titer 96 reagent. Fold-change (>1 vs   was further obtained for each of three values from NCIH99, U266B1 and ARH77, as a group.  RESULTS AND CONCLUSIONS: Hyperglycemia (20 vs 5 mM glucose) affected the fold-change of increased levels of TXNIP RNA (mean 1.4+0.2 ,  range 1.2-1.6) and ROS activity (mean  1.7+0.3, range 1.5-2.0) in NCIH929, ARH77 and U266B1 cells. As expected the TRX activity was reduced on average 0.8+0.15 fold (range 0.7-0.9 )  in the same cell lines. On the contrary, glucose induced an increase in TRX activity (1.6 fold) associated with decreased ROS activity (0.4 fold) independently from TXNIP RNA level (1.0 fold) in MC/CAR cell line. When DEX was added to cells in conditions of hyperglycemia (20 mM glucose) TXNIP RNA level decreased  ( mean 1.06+0.05, range 1.0-1.1, vs 1.4 w/o DEX) associated with decreased ROS activity (mean 0.86+0.5, range 0.5-1.4, vs 1.7 w/o DEX) in NCIH929, ARH77 and U266B1 cells. Ultimately, DEX notably reduced TRX activity (1.6 vs 1.2 fold w/o DEX) without any significant changes in TXNIP level and ROS activity in MC/CAR cells, implying a TXNIP-independent effect on this activity in this cell line. In conclusion, our study shows that glucose regulates the TXNIP-TRX-ROS axis in 3 out of 4 multiple myeloma cell lines and this effect is blunted by DEX, establishing ground for further investigation in this perspective.
Acidity-responsive gene delivery for “superfast” nuclear translocation and transfection with high efficiency
Authors: Jing-Yi Zhu, Xuan Zeng, Si-Yong Qin, Shuang-Shuang Wan, Hui-Zhen Jia, Ren-Xi Zhuo, Jun Feng, Xian-Zheng Zhang
Journal: Biomaterials (2016)
First Large Prospective Study For Patients With Primary Plasma Cell Leukemia: Bortezomib-Doxorubicine-Dexamethasone/Bortezomib-Cyclophosphamide-Dexamethasone Regimens As Induction Before Stem Cell Transplantation Followed By Consolidation With Lenalidomide-Bortezomib-Dex Or Allograft. (a study of the IFM group)
Authors: Bruno Royer, Florence Magrangeas, Bruno Lioure, Jean-Paul Fermand, Cyrille Hulin, Lionel Karlin, Sylvie Cailleres, Charles Dauriac, Margaret Macro, Marc Wetterwald, Laurent Garderet, Xavier Leleu, Philippe Moreau, Francois Guilhot, Jean-Gabriel Fuzibet, Mourad Tiab, Jean Fontan, Carine Chaleteix, Denis Caillot, Philippe Casassus, Richard Delarue, Karim Belhadj, Jean Pierre Marolleau, Murielle Roussel, Hervé Avet-Loiseau
Journal: Blood (2013)
The role of emotion in patient safety: Are we brave enough to scratch beneath the surface?
Authors: Jane Heyhoe, Yvonne Birks, Reema Harrison, Jane K O’Hara, Alison Cracknell, Rebecca Lawton
Journal: Journal of the Royal Society of Medicine (2015)

Healthcare professionals work in emotionally charged settings; yet, little is known about the role of emotion in ensuring safe patient care. This article presents current knowledge in this field, drawing upon psychological approaches and evidence from clinical settings. We explore the emotions that health professionals experience in relation to making a medical error and describe the impact on healthcare professionals and on their professional and patient relationships. We also explore how positive and negative emotions can contribute to clinical decision making and affect responses to clinical situations. Evidence to date suggests that emotion plays an integral role in patient safety. Implications for training, practice and research are discussed in addition to strategies to facilitate health services to understand and respond to the influence of emotion in clinical practice.
Tumor Heterogeneity—A ‘Contemporary Concept’ Founded on Historical Insights and Predictions
Authors: Danny R. Welch
Journal: Cancer Research (2016)

Abstract Heterogeneity is commonplace in all cancer types and at several levels—intrinsic (genetic), epigenetic, positional, and at the population level. The different subpopulations with a tumor mass communicate with each other and influence the behavior of other tumor cells both locally and at a distance. These properties have profound implications regarding the understanding of tumor behavior and how therapies are (or should be) administered. This brief commentary highlights the insightful review of Gloria Heppner and how it has influenced cancer research even three decades after it was published. Cancer Res; 76(1); 4–6. ©2016 AACR. See related article by Heppner, Cancer Res 1984;44:2259-65.
US panel narrows recommendations for low dose aspirin for cardiovascular disease prevention
Authors: Michael McCarthy
Journal: BMJ (2015)

Adults aged 50 to 59 who are at risk of cardiovascular disease should take low dose aspirin for primary prevention, the US Preventive Services Task Force has concluded in draft recommendations released on 15 September.1 2 Previously, the task force had recommended aspirin for men aged 45 to 79 for the prevention of myocardial infarction and for women aged 55 to 79 for the prevention of ischemic stroke.

An independent panel of experts on prevention and evidence based medicine was commissioned by the US Agency for Healthcare Research and Quality to draft recommendations for clinical preventive services. The new recommendations apply to adults without known cardiovascular disease who do not have conditions that increase their risk of bleeding, such as gastrointestinal ulcers, or who use drugs that increase the risk of bleeding.

In the draft document the panel recommended low dose aspirin for the primary prevention of cardiovascular disease in adults aged 50 to 59 years …
Airway management complications in children with difficult tracheal intubation from the Pediatric Difficult Intubation (PeDI) registry: a prospective cohort analysis
Authors: John Edem Fiadjoe, Akira Nishisaki, Narasimhan Jagannathan, Agnes I Hunyady, Robert S Greenberg, Paul I Reynolds, Maria E Matuszczak, Mohamed A Rehman, David M Polaner, Peter Szmuk, Vinay M Nadkarni, Francis X McGowan, Ronald S Litman, Pete G Kovatsis
Journal: The Lancet Respiratory Medicine (2015)
A multimodal Pepstatin A peptide-based nanoagent for the molecular imaging of P-glycoprotein in the brains of epilepsy rats
Authors: Xiangrong Yu, Jianhong Wang, Jiansheng Liu, Shun Shen, Zhonglian Cao, Jiawei Pan, Shuyi Zhou, Zhiqing Pang, Daoying Geng, Jun Zhang
Journal: Biomaterials (2015)